Month: <span>November 2025</span>
Month: November 2025

Psychometric evaluation of the Ontario Child Health Study Emotional Behavioural Scales (OCHS-EBS) in children and youth from an outpatient mental health setting

Psychiatry Res. 2025 Oct 28;354:116809. doi: 10.1016/j.psychres.2025.116809. Online ahead of print. ABSTRACT This paper describes the psychometric properties of the Ontario Child Health Study Emotional …

The Prevention of Developmental Delay and Xylitol (PDDaX) trial: study protocol of a nested cohort follow-up from the PPaX (Prevention of Prematurity and Xylitol) trial examining neurodevelopmental outcomes among offspring at 4-8 years of age in Malawi

Trials. 2025 Nov 14;26(1):506. doi: 10.1186/s13063-025-09204-y. ABSTRACT BACKGROUND: We recently conducted the cluster-randomized, Prevention of Prematurity and Xylitol (PPaX) trial which demonstrated a significant reduction …

Frequency of team simulation and reduction in maternal deaths following Safer Births Bundle of Care implementation-a prospective observational study

Adv Simul (Lond). 2025 Nov 14;10(1):56. doi: 10.1186/s41077-025-00387-7. ABSTRACT BACKGROUND: Safer Births Bundle of Care (SBBC) is a continuous quality improvement (CQI) program, implemented in …

High prevalence and pathogen-specific variations of co-infections in pediatric adenovirus pneumonia: a retrospective epidemiological analysis from Northern China

Ital J Pediatr. 2025 Nov 14;51(1):302. doi: 10.1186/s13052-025-02129-x. ABSTRACT BACKGROUND: To investigate the characteristics of co-infection pathogen profiles in children with adenovirus pneumonia and provide …

Effects of dietary management for medium-chain acyl-CoA dehydrogenase deficiency (MCADD) on eating behaviour in childhood, adolescence and young adulthood

BMC Nutr. 2025 Nov 14;11(1):213. doi: 10.1186/s40795-025-01209-9. ABSTRACT BACKGROUND: Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) is an autosomal recessive disorder of ß-oxidation. A loss of enzyme …

How a major discovery can become a public health failure when used subotptimally: lessons from early nirsevimab implementation

Ital J Pediatr. 2025 Nov 14;51(1):301. doi: 10.1186/s13052-025-02147-9. ABSTRACT BACKGROUND: In this Debate, based on our clinical data from the “pre-nirsevimab” and “first year of …

Automated reporting of primaquine dose efficacy, tolerability and safety for Plasmodium vivax malaria using a systematic review and individual patient data meta-analysis

Malar J. 2025 Nov 14;24(1):400. doi: 10.1186/s12936-025-05642-w. ABSTRACT BACKGROUND: The antirelapse efficacy of primaquine is related to the total dose administered, whereas the risks of …